AbCellera Biologics Inc. (ABCL)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: Canada
Exchange: NASDAQ
Market cap: $4.09B
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 5, 2026
Profit #1309 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 9.3% | 9.9% | 10.4% | 9.6% |
Growth #395 of 1484 companies
Payout #1117 of 1484 companies
Safety #931 of 1484 companies
Price #1399 of 1484 companies
